Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-143 for postsurgical pain after inguinal hernia repair
NCT06709612Phase 2Withdrawn
- Sponsor
- AmacaThera
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Hydrogel Systems
01
Overview
A Phase 2 trial of AMT-143 in Persistent postsurgical pain (PPSP), sponsored by AmacaThera. Planned start Jan 2025; status: withdrawn.
02
Drugs
AMT-143
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on NCT06709612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709612.